Baxter receives FDA clearance for new Actifuse bone graft substitute

Baxter has received FDA clearance of Actifuse Flow Bone Graft Substitute for use in a variety of orthopedic surgical procedures. Actifuse Flow utilizes the proprietary silicate-substituted technology of Baxter’s Actifuse Bone Graft Substitute, which enhances silicon levels to accelerate bone formation. Baxter expects Actifuse Flow to be available to U.S. customers by year-end.

https://thefly.com/landingPageNews.php?id=2786661